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Atherosclerosis and CVD are driven by endothelial dys-
function, a condition associated with low-grade systemic 
inflammation and characterized by inappropriate inflam-
matory activation of vascular endothelial cells (ECs). This 
disruption of endothelial homeostasis is coupled with im-
paired anti-inflammatory and antioxidant defense capacity, 
resulting in reduced resistance to oxidative and inflamma-
tory insult, excessive reactive oxygen species (ROS) pro-
duction, and development of oxidative stress (1). Thus, 
improving or maintaining endogenous mechanisms of en-
dothelial protection may offer a strategy to mitigate devel-
opment of CVD.
ECs are continuously challenged by the complex molecu-
lar milieu of circulating nutrients, cells, and blood con-
stituents, including TG-rich lipoproteins (TRLs) [VLDLs, 
chylomicrons, and chylomicron remnants (CMRs)]. TRLs 
increase postprandially, but while endogenous lipopro-
tein involvement in CVD development is well-documented, 
how exogenous TRLs carrying dietary fats influence endo-
thelial homeostasis is far less well understood, despite 
strong evidence implicating CMRs in the initiation of 
endothelial dysfunction (2–6). This is thought to involve 
a process now termed “postprandial inflammation” (7) in 
which CMRs migrate into the subendothelial space, ac-
tivate circulating leukocytes, and increase immune cell 
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Preparation and characterization of A-CRLPs
A-CRLPs containing ApoE were prepared as detailed previ-
ously (17). We and others have shown that these particles closely 
resemble physiological lipoproteins in terms of their size, den-
sity, and lipid composition and that they are cleared from the 
circulation in vivo in a manner that is identical to physiological 
particles (18–21). TGs were extracted  from menhaden fish oil, 
DHASCO® [a blend of DHA from Crypthecodinium cohnii with 
high oleic sunflower oil; now marketed as Life’s DHA (Martek 
Biosciences Corporation, Columbia, MD)], corn oil, and unre-
fined palm oil (KTC Edibles Ltd., UK) using SupelcleanTM LC-Diol 
SPE tubes. Oils were dissolved 1:10 in hexane, applied to precon-
ditioned columns, and the flow-through discarded. TGs were 
eluted in 9:1 hexane:dichloromethane, assessed for purity by 
thin-layer chromatography, and stored under argon at 80°C (17).
Human plasma (National Blood Service, Colindale, UK) was 
prepared by ultracentrifugation to remove chylomicrons, CMRs, 
VLDLs, and IDLs and the remnant-free plasma stored at 20°C. 
A-CRLPs containing human ApoE were prepared with TGs from 
fish, DHASCO®, and corn and palm oils by ultracentrifugation, 
as detailed previously (17), using 70% TG, 2% cholesterol, 3% 
cholesteryl ester, and 25% phospholipids by weight. Briefly, 50 mg 
of emulsified lipids in 4.25 ml 25 mM Tricine (pH 7.4) were soni-
cated for 20 min at 55°C, 1.4 g KBr added, and samples overlaid 
with 2.5 ml 1.063 g/ml, 2.5 ml 1.020 g/ml, and 3 ml 1.006 g/ml 
saline prior to ultracentrifugation at 11,000 rpm for 20 min 
(20°C) in a SW40 Ti rotor (Beckman Coulter). The upper 1 ml 
was replaced with 1.006 g/ml NaCl and the tubes centrifuged at 
23,500 rpm (1 h, 20°C). The top CRLP layer was mixed with 4 ml 
remnant-free plasma for 4 h at 37°C (for ApoE transfer), layered 
beneath 1.006 g/ml NaCl,  centrifuged  at  30,000  rpm  for  16 h 
(12°C), and then washed with 1.006 g/ml NaCl by ultracentrifu-
gation at 30,000 rpm for 3 h at 12°C. A remnant control was 
prepared in parallel using remnant-free plasma without lipids. 
The antioxidant compound, probucol (1 mg), was incorporated 
into separate preparations of fish, DHASCO®, and corn A-CRLPs 
to allow evaluation of their cellular effects when protected from 
oxidation. The total cholesterol and TG contents of A-CRLPs 
and probucol-containing A-CRLPs were determined using com-
mercially  available  enzymatic  assays  (InfinityTM cholesterol and 
InfinityTM triglyceride reagents; ThermoFisher, UK) as per the 
manufacturer’s instructions, and their oxidation state assessed 
by measuring malondialdehyde using the thiobarbituric acid 
reactive substance (TBARS) assay, as described previously (17) 
(see supplementary Fig. 1).
Cell culture and experimental incubations
HAECs were maintained in EGM-2 according to the supplier’s 
instructions (Lonza, Visp, Switzerland) and used for experiments 
at passages 6–8. Human umbilical vein endothelial cells (HUVECs) 
were isolated and cultured in M199 supplemented with 20% FCS 
and ECGS as previously described (22, 23), and used at passage 
2. Prior to incubation with A-CRLPs, HAECs were serum-starved 
for 5 h in basal medium (EBM; Lonza) and HUVECs were 
serum-depleted for 1 h in 1% FBS-M199 (Gibco, ThermoFisher, 
UK) unless otherwise stated. Experimental treatments were pre-
pared in basal medium except for those used in experiments 
measuring ROS production. A-CRLP incubations were at 280 M 
TG for 4 or 16 h unless indicated otherwise.
Microarray
Experimental details of a preliminary microarray performed 
in HAECs exposed to A-CRLPs of differing TG composition, to-
gether with its statistical analysis, are given in the supplementary 
file. The dataset has been placed in the GEO repository (record 
trans-endothelial migration, potentially precipitating mac-
rophage foam cell formation (3, 7).
The composition of CMRs directly reflects dietary lipid 
intake and, in individuals consuming a typical Western 
diet, ECs are chronically exposed to these TRLs for up to 
18 h per day, so an improved understanding of their 
molecular actions on the endothelium is warranted. Stud-
ies using ex vivo postprandial TRL fractions and artificial 
model CMRs have demonstrated that these particles can 
trigger activation of MAPKs in ECs and influence EC in-
flammatory status (2, 8–12), although how these signaling 
pathways are coupled to altered gene expression and EC 
function  is  not  defined. There  are  also  suggestions  that 
CMRs may exert protective or deleterious effects depend-
ing upon lipid content and pathophysiological context 
(3, 13), but the molecular details of their direct actions on 
human ECs remain elusive and the potential for divergent 
effects of CMRs relating  to  their  specific FA content has 
not been addressed (3, 14). In this respect, we have shown 
that the FA composition of a high-fat test meal influences 
postprandial lipemia in healthy men and that n-3 PUFAs, 
particularly DHA, reduce plasma indices of oxidative stress 
when ingested as part of a high-fat meal (15), providing 
support for the purported relative beneficial actions of n-3 
PUFAs in vivo (16). However, whether CMRs containing 
n-3 PUFAs impact vascular homeostasis through direct 
actions on ECs, if these effects differ from those of CMRs 
rich in other FAs, and how this operates at the molecular 
level have not been established.
Because ex vivo TRL fractions contain a complex mix-
ture of both exogenous and endogenous lipoproteins, dis-
tinguishing the actions of VLDLs and their remnants from 
those of CMRs is challenging. Here, we have used our vali-
dated tractable model of ApoE-containing CMRs, “artificial 
TG-rich CMR-like particles” (A-CRLPs) (17), to establish 
whether they exert differential effects on primary human 
aortic ECs (HAECs) according to their FA composition, 
and have investigated the underlying molecular mecha-
nisms. We have compared the effects of A-CRLPs con-
taining TGs extracted from natural dietary oils relatively 
enriched in n-3 PUFAs, n-6 PUFAs, or saturated FAs (SFAs) 
to  test  the  overarching  hypothesis  that  model  artificial 
CMRs carrying n-3 PUFAs exert greater cytoprotective ef-
fects than those rich in n-6 PUFAs or SFAs. This compara-
tive analysis showed that A-CRLPs of varying FA content 
switch EC gene expression toward a program of antioxi-
dant defense, dominated by induction of the nuclear fac-
tor erythroid 2-related factor 2 (Nrf2)-dependent gene, 
heme oxygenase-1 (HO-1), with n-3 PUFA-containing par-
ticles exhibiting the greatest efficacy. Our studies identify 
a new redox-dependent pathway through which model 
postprandial TRLs regulate EC gene expression and this 
may provide a molecular explanation for the relative ben-
eficial effects of n-3 PUFAs in the postprandial phase.
MATERIALS AND METHODS
Chemicals and reagents were from Sigma-Aldrich (Gillingham, 
UK) unless otherwise stated.
 by guest, on August 17, 2016
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2016/05/16/jlr.M067108.DC1
Supplemental Material can be found at:
1206 Journal of Lipid Research Volume 57, 2016
aperture = 0.75) objective lens. Mean Nrf2 intensity per DAPI-
defined nucleus was quantified using Volocity® 3D image analysis 
software (PerkinElmer, Waltham, MA).
Statistical analysis
Data were collated in Microsoft Excel (MicroSoft, USA) with 
appropriate statistical analyses performed using GraphPad Prism 
(version 6.0; GraphPad Software) as detailed in the figure leg-
ends. Data are expressed as mean ± SEM and P < 0.05 was consid-
ered statistically significant.
RESULTS
A-CRLPs enriched in n-3 PUFAs induce HO-1 and reduce 
TXNIP and VCAM-1 expression to a greater extent than 
particles enriched in n-6 PUFAs or SFAs
Characterization of the model artificial TG-rich A-CRLPs 
used in this study confirmed that there was no significant 
variation in TG:cholesterol ratios between different prepa-
rations (supplementary Fig. 1) (17) and that their FA com-
positions were each reflective of the oil from which the 
TGs were extracted (not shown) (17). As anticipated, the 
n-3 PUFA-containing particles prepared using TGs from 
fish  and DHASCO® oils were more oxidized than those 
containing corn or palm oil TGs, and assessment of EC 
viability showed no deleterious effects of any of the 
A-CRLPs over a range of TG concentrations (supplementary 
Fig. 1). In normal healthy humans, the TG content of the 
postprandial CMR fraction at 5 h, corresponding to peak 
lipemia, approximates 300 M (26); hence, A-CRLPs were 
used in subsequent experiments at the physiologically rel-
evant concentration of 280 M TG.
A preliminary microarray analysis assessed the compar-
ative effects of A-CRLPs of differing FA composition on 
global HAEC gene expression (data and statistical analy-
sis in supplementary Tables 4–7). Transcripts showing 
increased expression (>1.5-fold) 4 h after exposure to 
A-CRLPs included those encoding antioxidant proteins 
and protective molecules such as metallothioneins. Nrf2 
target genes involved in antioxidant defense, such as HO-1, 
sulfiredoxin (SRX), and thioredoxin reductase (TXR), were 
particularly affected, with n-3 PUFA-containing A-CRLPs 
generally promoting greater fold induction than those 
enriched in n-6 PUFAs or SFAs. HO-1, for example, was 
upregulated by 6.84-fold (P = 0.004), 5.48-fold (P = 0.054), 
3.78-fold (P = 0.0074), and 1.86-fold (P = 0.11) by fish, 
DHASCO®, corn, and palm A-CRLPs, respectively. Sub-
sequent extensive and independent quantitative (q)PCR 
validation of selected genes  identified by the array con-
firmed  that  fish  and  DHASCO®  A-CRLPs  significantly 
increased expression of HO-1, SRX, and TXR mRNAs in 
HAECs after 4 h, with particularly robust effects on HO-1 
expression (Fig. 1A–C), an antioxidant enzyme with car-
diovascular protective properties (27–32). Corn and palm 
A-CRLPs promoted smaller, but nonetheless reproduc-
ible, increases in both HO-1 and SRX mRNAs (which did 
not  reach  statistical  significance when  analyzed  along-
side the marked effects of fish and DHASCO® A-CRLPs) 
GSE80067;  http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?to
ken=alateuokffyxtgp&acc=GSE80067).
ROS assays
Confluent ECs in 96-well plates were incubated with A-CRLPs 
for the times indicated in full growth medium without prior 
serum depletion. For incubations up to 1 h, cells were preloaded 
with dihydrorhodamine-1,2,3 (DHR; 10 M) for 20 min before 
exposure to A-CRLPs. For longer incubations, ECs were chal-
lenged with A-CRLPs prior to addition of 10 M DHR or 10 M 
2′7′-dichlorofluorescein-diacetate (DCF-DA) for 20 min, or 5 M 
MitoSOX (ThermoFisher) for 10 min, as indicated. After wash-
ing in PBS, fluorescence was measured in a plate reader (Tecan, 
Switzerland) using excitation/emission wavelengths of 205/230 nm 
for DHR and DCF-DA, and 510/580 nm for MitoSOX.
siRNA
HAECs in 6-well plates were cultured in EGM-2 until 50% con-
fluent and washed with OptiMEM (Life Technologies, UK). Cells 
were transfected for 4 h with scrambled negative control siRNA or 
siRNAs targeting NADPH oxidase (NOX)4, p38MAPK, PPAR/, 
Akt1, or Akt2 (20 nM) complexed to ESCORT III in OptiMEM 
(see supplementary Table 1). Transfection media were replaced 
with EGM-2 and experimental incubations performed 48–72 h 
posttransfection.
PCR
RNA was extracted using the GenElute™ mammalian total 
RNA miniprep kit according to the manufacturer’s instructions. 
Reverse transcription of 0.5 g RNA per sample with 1 M oligo 
dT primer (MWG Eurofins) and 1 U/ml RNaseOUT (Life Tech-
nologies; ThermoFisher) was performed with the OmniscriptRT 
kit (Qiagen, Manchester, UK) in a total reaction volume of 20 l 
for 1 h (37°C). Real-time PCR using SYBR® Green JumpStart™ 
Taq ReadyMix™ with MgCl2 was performed in a Chromo4 ther-
mocycler (Bio-Rad, Hemel Hempstead, UK) using primers listed 
in supplementary Table 2. Data were processed using Opticon 
Monitor 3 software and normalized to the validated reference 
gene, GAPDH.
Western blotting
Near confluent EC monolayers treated as indicated were 
washed with ice-cold PBS containing 0.4 mM Na3VO4 and then 
lysed in 76.5 mM Tris-HCl containing 10% (v/v) glycerol, 2% (w/v) 
SDS, 1 mM Na3VO4, and 10 l/ml protease inhibitor cocktail on 
ice for 10 min. Proteins (30 g) were resolved by SDS-PAGE (10%), 
transferred to polyvinylidene difluoride membranes, and immu-
noprobing was performed as described previously (24, 25). Mem-
branes were blocked in 5% milk or 3% BSA, as appropriate, prior 
to incubation with primary antibodies (supplementary Table 3).
Immunofluorescence microscopy
HUVECs on 1% gelatin-coated glass coverslips were treated as 
indicated, washed with PBS, fixed in paraformaldehyde (4%), 
permeabilized with 0.1% Triton X-100, and then blocked in 3% 
BSA/1% goat serum in PBS for 30 min. Coverslips were washed 
in PBS/0.1% Tween (three times for 5 min) and incubated with 
anti-Nrf2 antibody (1:200; Abcam, Cambridge, UK) diluted in 
3% BSA/1% goat  serum  for 1 h. Following  further washing, 
coverslips were incubated for 1 h with anti-rabbit Alexafluor 
594 secondary antibody (1:1,000). Nuclei were stained with 
4′,6-diamidino-2-phenylindole (DAPI) and images collected 
using an SP5 confocal microscope and Leica Application Suite 
advanced fluorescence software version 2.6 (Leica Microsystems, 
Milton Keynes, UK) with a 40× HCX PL FLUOTAR PH2 (numerical 
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Fig. 1. A-CRLPs modulate cytoprotective gene expression and elevate ROS production dependent upon 
oxidative state. A–D: HAECs were serum starved for 5 h and then incubated with A-CRLPs (280 M TG) for 
4 h. HO-1, SRX, TXR, and TXNIP mRNAs were quantified by qPCR and normalized to GAPDH (mean fold 
change versus RC ± SEM; n = 4–5. Black bars: remnant control (RC), fish (F), DHASCO® (DH), corn (C), 
and palm (P) A-CRLPs. Striped bars: probucol-fish (pF), probucol-DHASCO® (pDH), and probucol-corn 
(pC) A-CRLPs. One-way ANOVA with Dunnett’s multiple comparisons test, compared with RC: *P < 0.05, 
**P < 0.01, ****P < 0.0001. E, F: DHR was used to measure ROS/RNS production, presented as mean fold 
change  relative  to  RC  ±  SEM  (n  =  6  for  A-CRLPs,  n  =  3  for  probucol-A-CRLPs  with  each  experiment   
performed in technical quintuplet). Two-way ANOVA, RC versus A-CRLPs indicated: *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001. For palm A-CRLPs versus other compositions, $P < 0.05.
(Fig. 1A, B), and also increased TXR expression signifi-
cantly (Fig. 1C). Of the transcripts identified by microar-
ray as downregulated by A-CRLP treatment (supplementary 
Tables 4–7), thioredoxin interacting protein (TXNIP) was 
of particular interest because it acts as an endogenous 
inhibitor of thioredoxin by preventing its ability to scav-
enge ROS (33) and promotes inflammatory activation of 
ECs (34). Additional experiments confirmed that fish and 
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the  importance of oxidative state/ROS production for 
A-CRLP-driven gene expression. Because of the high level 
of HO-1 induction observed compared with that of the 
other validated genes, and the divergent effects of n-3 PUFA 
A-CRLPs on this versus the other particles (Figs. 1, 2), we 
focused our attention on delineating the mechanisms 
controlling HO-1 expression. First, we examined potential 
sources of the ROS produced in A-CRLP-treated ECs. Ini-
tial experiments in HUVECs showed that the antioxidant, 
N-acetyl cysteine, and the general flavoprotein inhibitor, 
diphenyleneiodonium, abrogated the effects of A-CRLPs 
on HO-1 expression, whereas apocynin had no effect at a 
concentration known to inhibit NOX2 (39) (supplemen-
tary Fig. 3). Using human monocyte cDNA as a positive 
control, HAECs were shown to express low/borderline 
detectable levels of NOX2 mRNA (not shown), agreeing 
with reports that endothelial NOX4 expression is 100-fold 
greater than that of NOX2 (40). Experiments in HAECs 
confirmed that diphenyleneiodonium abrogated A-CRLP-
induced HO-1 expression in these cells, whereas the xan-
thine oxidase inhibitor, allopurinol, had no effect (Fig. 3A). 
These data collectively imply a predominant role for 
NOX4 in A-CRLP-stimulated HO-1 expression. In addition, 
DHASCO® A-CRLPs reduced, while palm A-CRLPs in-
creased, NOX4 mRNA after 16 h (supplementary Fig. 3), 
indicating divergent effects of sustained exposure to n-3 
PUFA or SFA A-CRLPs on NOX4 expression.
To investigate the potential importance of NOX4 for 
regulating HO-1 induction by A-CRLPs, we used NOX4-
targeted siRNA, which decreased endogenous NOX4 
expression by 83% (supplementary Fig. 4A). These stud-
ies showed that NOX4 siRNA, but not noncoding scram-
bled siRNA, significantly reduced the ability of A-CRLPs to 
increase HO-1 expression at the mRNA level (Fig. 3C, D) 
with a similar trend observed at the protein level (Fig. 3B). 
NOX4 silencing did not completely abrogate the increased 
HO-1 levels evident in A-CRLP-stimulated cells, implying 
likely involvement of other mechanisms in this response. 
Accordingly, we used the mitochondrial superoxide scav-
enger, MitoTEMPO, to investigate the potential contri-
bution of mitochondrial ROS generation. As shown in 
Fig. 3E–G, MitoTEMPO treatment reduced the ability of 
fish, DHASCO®, and corn A-CRLPs, but not palm A-CRLPs, 
to increase HO-1 expression, suggesting that mitochondrial 
ROS regulate HO-1 induction in response to PUFA-rich 
A-CRLPs, but not to SFA-rich palm A-CRLPs, which seem 
to depend primarily upon NOX4 activity for driving HO-1 
induction. To verify that MitoTEMPO reduced A-CRLP-
induced ROS production, we used the generic probe, 
DCF-DA,  and  the  more  specific  superoxide  indicator, 
MitoSOX. In vehicle (DMSO) preincubated cells, DHASCO® 
A-CRLPs induced a significant increase in both DCF and 
MitoSOX fluorescence, but did not significantly increase 
either signal in cells preincubated with MitoTEMPO 
(Fig. 3H). Taken together, these data reveal a key role for 
NOX4 activity in regulating A-CRLP-stimulated HO-1 induc-
tion in ECs and indicate that both NOX4 activity and mito-
chondrial ROS contribute to HO-1 induction following 
exposure to A-CRLPs containing PUFAs.
DHASCO® A-CRLPs  significantly decreased TXNIP ex-
pression, with corn A-CRLPs showing a trend toward TXNIP 
reduction (P = 0.06) and SFA-containing A-CRLPs without 
effect (Fig. 1D). Incorporation of the antioxidant, pro-
bucol, which reduced the malondialdehyde content of 
PUFA-containing particles (supplementary Fig. 1), pre-
vented  A-CRLPs  from  significantly  affecting  gene  ex-
pression, demonstrating that these actions depend upon 
A-CRLP oxidation state and/or their ability to undergo 
oxidation during experimental incubations (Fig. 1A–D). 
Given the known importance of ROS and reactive nitro-
gen species (RNS) in signal transduction, we then used 
the general probe, DHR, and showed that all A-CRLPs 
modestly, but significantly, increased ROS/RNS genera-
tion within 60 min, responses that were sustained for 24 h 
(Fig. 1E, F). As anticipated, PUFA-containing A-CRLPs in-
creased ROS/RNS levels to a greater extent than SFA-rich 
palm A-CRLPs, while probucol-containing particles had 
no detectable effect (Fig. 1E, F). Together, these data 
imply that both TG composition and oxidative state are 
important determinants of the HAEC response to A-CRLPs.
Further studies demonstrated that the pattern of A-CRLP-
induced expression of HO-1, SRX, and TXR in HAECs 
after 16 h was similar to that at 4 h (Fig. 2A–C) and that 
expression of NADPH quinone oxidoreductase-1, another 
well-characterized Nrf2 target gene (35) that was not 
induced at 4 h (not shown), was increased by more pro-
longed A-CRLP treatment (Fig. 2D). As at 4 h (Fig. 1), n-3 
PUFA fish  and DHASCO® A-CRLPs  showed  significantly 
greater ability to induce HO-1 and SXR at 16 h than n-6 
PUFA- or SFA-enriched A-CRLPs, with the latter showing a 
consistent trend toward HO-1 and SRX induction (albeit 
not  statistically  significant  in direct  comparison  to  the 
effects of n-3 PUFA-containing particles). Similarly, all 
particles reduced TXNIP mRNA after 16 h, but fish and 
DHASCO® A-CRLPs did so to a significantly greater extent 
than corn and palm A-CRLPs (Fig. 2E). The effects of 
A-CRLPs on cytoprotective gene expression at 16 h were 
also accompanied by reduced levels of vascular cell adhe-
sion molecule-1 (VCAM-1) (Fig. 2F), which, along with 
intracellular adhesion molecule-1, is important for sup-
porting inflammatory changes in ECs (16, 36–38). Whereas 
A-CRLPs did not modify intracellular adhesion molecule-1 
levels (not shown) VCAM-1 mRNA expression followed a 
similar pattern to that of TXNIP and was reduced by 
exposure to all CRLP types, with n-3 PUFA-containing 
DHASCO® A-CRLPs causing a significantly greater inhibi-
tion than SFA-rich palm A-CRLPs (Fig. 2F). Thus, upregu-
lation of Nrf2-regulated genes by A-CRLPs is associated 
with a concomitant downregulation in expression of genes 
with pro-inflammatory functions, and particles containing 
n-3 PUFAs appear to be more efficacious in these respects 
than those rich in SFAs.
NOX4 activity and mitochondrial ROS regulate  
A-CRLP-induced HO-1 expression
Our data show that A-CRLPs induce antioxidant re-
sponse gene expression in HAECs and increase ROS pro-
duction, with probucol-containing particles corroborating 
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expression (not shown), verifying NOX4’s importance as 
a regulator of Nrf2-dependent gene expression in ECs 
exposed to A-CRLPs.
Because other stimuli have been reported to induce 
HO-1 in HUVECs via Nrf2- and ROS-dependent mechanisms 
downstream of Akt or ERK (41), we determined whether 
similar pathways regulate HO-1 expression in aortic ECs 
challenged with A-CRLPs. Incubation with PUFA- or SFA-
rich A-CRLPs increased phosphorylation of both Akt and 
ERK1/2 (supplementary Fig. 5). Next, we used a pharma-
cological  inhibitor of Akt1 and Akt2 (Akt1/2i) and an 
inhibitor of MAPK kinase 1 (MEK; PD184352) to investigate 
whether Akt and/or the MEK/ERK pathway contribute 
to A-CRLP-induced HO-1 expression. At concentrations 
that abrogated A-CRLP-induced kinase phosphorylation 
A-CRLP-induced HO-1 expression is dependent on Nrf2, 
but not on Akt or ERK1/2
Having demonstrated  the  significance of ROS genera-
tion for HO-1 induction by A-CRLPs, we next evaluated 
the functional importance of Nrf2. As shown in Fig. 4A, 
transient transfection with siRNA directed against Nrf2, 
but not control siRNA, completely abrogated the increased 
HO-1 protein expression detected after incubation with 
fish or DHASCO® A-CRLPs. In addition, while Nrf2 mRNA 
was unaffected by A-CRLPs (not shown), Nrf2 protein 
expression was increased in cells exposed to n-3 PUFA-
containing particles, and attenuated by Nrf2 siRNA (Fig. 4A), 
consistent with a mechanism involving posttranslational 
stabilization of Nrf2 upon A-CRLP treatment. Treatment 
with NOX4 siRNA also reduced A-CRLP-induced Nrf2 
Fig. 2. Differential effects of A-CRLPs with different FA compositions on gene expression in aortic ECs. 
HAECs were incubated with A-CRLPs (280 M TG) for 16 h and mRNAs for the genes indicated in (A–F) 
measured by qPCR and normalized to GAPDH. Data are mean fold change from RC (±SEM; n = 5). One-way 
ANOVA with Tukey’s multiple comparisons test versus RC: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 
and compared with group(s) indicated: $P < 0.05, $$P < 0.01, $$$P < 0.001.
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of individual Akt isoforms (42) and the nonselectivity of 
Akt1/2i prompted us to investigate the relative involvement 
of Akt1 versus Akt2 using specific siRNAs targeting these 
isoforms (see supplementary Fig. 6A, B). Unexpectedly, 
Fig. 3. A-CRLP-driven HO-1 expression is controlled by NOX4 and mitochondrial ROS. A: After serum 
starvation, HAECs were pretreated with DMSO (vehicle), 5 M diphenyleneiodonium, or 200 M allopuri-
nol for 1 h and then incubated with remnant control (RC), fish (F), or DHASCO® (DH) A-CRLPs (280 M TG) 
in the continued presence or absence of inhibitor for 4 h. Representative HO-1 and -actin blots from three 
independent  experiments  are  shown. B–D: HAECs  transfected with  scrambled  (scr/sc)  siRNA or NOX4 
(N4) siRNA were serum-starved then incubated with A-CRLPs for 4 h. B: Representative Western blots from 
three independent experiments. C, D: qPCR for HO-1 mRNA normalized to GAPDH presented as fold 
change of RC, mean ± SEM (n = 3). Two-way ANOVA with Bonferroni’s multiple comparisons test, scr versus 
NOX4 siRNA; $P < 0.05, $$P < 0.01, $$$$P < 0.0001. RC versus A-CRLPs: *P < 0.05, ***P < 0.001, ****P < 0.0001. 
E–G: Serum-starved HAECs were pretreated with DMSO (v) or 25 M MitoTEMPO (MT) for 1 h then incubated 
with A-CRLPs for 4 h in the presence of DMSO or MT. E, F: qPCR for HO-1 mRNA normalized to GAPDH 
presented as fold change relative to RC, mean ± SEM, n = 3. Two-way ANOVA with Bonferroni’s multiple 
comparisons test, v versus MT; $P < 0.05, $$$P < 0.001. RC versus A-CRLP indicated; *P < 0.05, ***P < 0.001, 
****P < 0.0001. G: Representative Western blots. H: HUVECs were pretreated with DMSO (vehicle) or 25 M 
MitoTEMPO then incubated with RC or DHASCO® (DH) A-CRLPs in the presence of vehicle/MitoTEMPO 
for 2 h prior to loading with the ROS probe, 2′7′-DCF-DA (DCF), or MitoSOX (MtSOX) as indicated. Data 
are mean fold change relative to RC ± SEM (n = 3 with each experiment performed in technical quintuplet). 
Two-way ANOVA with Bonferroni’s multiple comparisons test, RC versus DHASCO®; *P < 0.05.
(see supplementary Fig. 6), neither inhibitor significantly 
modulated A-CRLP-driven HO-1 mRNA expression (Fig. 4B), 
suggesting that these pathways are not coupled to altered 
HO-1 expression in HAECs. Reports of opposing functions 
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activation in other cell types (43), but whether this path-
way regulates Nrf2-responsive genes in ECs exposed to 
model dietary lipoproteins is not known. Similarly, phar-
macological agonists of the lipid-sensing nuclear receptor, 
PPAR/ (44), can increase HO-1 expression (45, 46), but 
the role of endogenous PPAR/ in controlling HO-1 
in A-CRLP-challenged ECs  is undefined. Experiments  in 
HAECs showed that PUFA-containing A-CRLPs significantly 
increased p38MAPK phosphorylation and that this was 
reduced when the particles contained probucol (Fig. 5A), 
suggesting that activation of the p38MAPK pathway is at least 
partly dependent upon the oxidation state of the parti-
cles. A-CRLPs containing SFAs also consistently increased 
p38MAPK  phosphorylation,  although  this  did  not  quite 
reach  significance  following  statistical  analysis of  com-
bined densitometry data. Selective inhibitors of p38MAPK 
(SB202190) and PPAR/ (GSK0660) were then used to 
examine involvement in A-CRLP-induced HO-1 induc-
tion. Neither SB202190 [which effectively reduced p38MAPK 
phosphorylation (supplementary Fig. 6)] nor GSK0660 
influenced basal HO-1 expression, but both inhibitors 
reduced A-CRLP-induced HO-1 induction at the pro-
tein (Fig. 5B) and mRNA levels (not shown). Next, we 
Akt1 knockdown resulted in an 5-fold increase in basal 
HO-1 mRNA expression (supplementary Fig. 7) and this en-
hancement in expression was evident across all experimen-
tal samples at both mRNA and protein levels (Fig. 4C, D, 
respectively). Akt1 siRNA had no inhibitory effect on 
Nrf2 protein induction by n-3 PUFA-containing A-CRLPs 
(Fig. 4D) and silencing of Akt2, in contrast to Akt1, had no 
effect on basal HO-1 expression (supplementary Fig. 7), 
nor did  it  significantly  affect A-CRLP-stimulated HO-1 
induction (Fig. 4C). These data suggest that Akt1 operates 
as a negative regulator of HO-1 expression in aortic ECs, 
and additionally demonstrate that the stimulatory effects 
of A-CRLPs on Nrf2 and downstream HO-1 expression 
are independent of Akt1/2 activity.
p38MAPK and PPAR/ cooperatively regulate  
A-CRLP-induced HO-1 expression
We have previously shown that A-CRLPs trigger acute 
activation of p38 MAPK (p38MAPK) in HUVECs (8) and 
that p38MAPK regulates beneficial EC functions, including 
proliferation and migration (24). While p38MAPK can con-
tribute to pro-inflammatory pathways upstream of nuclear 
factor-B, there is also evidence linking p38MAPK to Nrf2 
Fig. 4. HO-1 induction by A-CRLPs is Nrf2 dependent but independent of Akt and ERK. A: HAECs trans-
fected with 20 nM noncoding (scr) or Nrf2 siRNA were incubated with remnant control (RC), fish (F), or 
DHASCO® (DH) A-CRLPs (280 M TG) for 7 h. Representative blots from three independent experiments 
are shown. B: Serum-starved HAECs were preincubated with DMSO (vehicle), 1 M Akt1/2i, or 1 M 
PD184352 (PD-MEKi) for 1 h then incubated with A-CRLPs for 4 h in the continued presence or absence of 
inhibitor. HO-1 mRNA expression normalized to GAPDH is presented as fold change relative to RC (mean ±  
SEM, n = 3). Two-way ANOVA with Bonferroni’s multiple comparisons  test,  vehicle  versus  inhibitors not 
significant (NS). RC versus A-CRLP indicated: **P < 0.01, ***P < 0.001, ****P < 0.0001. C, D: HAECs trans-
fected with 20 nM noncoding (scr), Akt1, or Akt2 siRNA were serum starved then incubated with A-CRLPs 
for 4 h. C: HO-1 mRNA normalized to GAPDH (fold change relative to RC; mean ± SEM, n = 4). Two-way 
ANOVA with Bonferroni’s multiple comparisons test, scr versus Akt1 siRNA: $P < 0.05. RC versus CRLP: 
*P < 0.05, ***P < 0.001, ****P < 0.0001. D: Representative Western blots from four independent experiments 
are shown for Nrf2, Akt1, HO-1, and -actin.
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and nuclear localization of Nrf2. These effects were not 
modified  by  pharmacological  inhibition  of  Akt  with 
Akt1/2i,  confirming  that  increased  Akt  activity  is  not  
required for A-CRLP-stimulated Nrf2 activation, but were 
abolished by incubation with a combination of SB202190 
and GSK0660 (Fig. 6A, B). Simultaneous inhibition of 
p38MAPK and PPAR/ also resulted in near complete 
abrogation of HO-1 protein/mRNA induction by n-3 PUFA-
containing A-CRLPs and total inhibition of the less robust 
HO-1 induction by A-CRLPs rich in n-6 PUFAs or SFAs 
(Fig. 6C–E). Together, these data demonstrate that p38MAPK 
and PPAR/ cooperate to control Nrf2-dependent EC 
HO-1 expression in response to A-CRLPs.
corroborated  these  findings  using  targeted  siRNAs  (see 
supplementary Fig. 4) and showed that knockdown of 
either p38MAPK (the principal functional isoform in ECs) or 
PPAR/ significantly reduced the increased HO-1 mRNA 
evident in cells exposed to A-CRLPs (Fig. 5C), confirming 
their importance as key regulators of A-CRLP-stimulated 
HO-1 expression.
To determine the relevance of p38MAPK and PPAR/ 
activities proximal to Nrf2 activation, we used immunofluo-
rescence to monitor Nrf2 in ECs exposed to DHASCO® 
A-CRLPs (Fig. 6A, B). In keeping with the Nrf2-dependency 
of A-CRLP-induced Nrf2 and HO-1 expression (Fig. 4), 
n-3 PUFA-containing particles increased both expression 
Fig. 5. A-CRLP-induced HO-1 expression is regulated by p38MAPK and PPAR/. A: Serum-starved HAECs 
were incubated with remnant control (RC), fish (F), DHASCO® (DH), probucol-DHASCO® (pDH), corn 
(C), probucol-corn (pC), or palm (P) A-CRLPs at 280 M TG for 10 min. Representative Western blots and 
densitometry analysis are shown for phospho- and total p38MAPK (n = 3–4) *P < 0.05 versus RC. B: Serum-starved 
HAECs were pretreated with vehicle, 1 M SB202190, or 1 M GSK0660 for 1 h prior to a 4 h A-CRLP incuba-
tion in the absence/presence of inhibitor. Representative blots are shown (n = 3). C, D: HAECs were trans-
fected with 20 nM noncoding (scr), MAPK14 (p38MAPK), or PPAR/ siRNA and then incubated with A-CRLPs 
for 4 h. HO-1 mRNA normalized to GAPDH is given as fold change relative to RC (mean ± SEM, n = 3–4). 
Two-way ANOVA with Bonferroni’s multiple comparisons test, scr versus p38MAPK and scr versus PPAR/ as 
indicated: $P < 0.05, $$P < 0.01, $$$P < 0.001. RC versus A-CRLP: **P < 0.01, ***P < 0.001, ****P < 0.0001.
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containing n-3 PUFAs are particularly effective compared 
with those rich in either n-6 PUFAs or SFAs.
Nrf2 is a transcription factor that controls the adaptive 
response to endogenous and exogenous oxidative stress. 
Here, we identified several Nrf2-dependent genes modified 
by A-CRLPs, including antioxidant and cytoprotective mol-
ecules, demonstrating that modulation of Nrf2-regulated 
targets is one key EC response to lipoprotein challenge. 
HO-1 is a multifunctional enzyme, generating products 
DISCUSSION
To our knowledge, this is the first detailed study explor-
ing the effects of model CMRs on adult aortic ECs and 
provides novel mechanistic insight into how dietary 
lipoproteins of differing FA composition influence adult 
ECs. We show, using model A-CRLPs prepared using TGs 
extracted from four natural dietary oils, that A-CRLPs 
stimulate protective pathways in ECs and that particles 
Fig. 6. A-CRLPs increase Nrf2 expression and nuclear translocation via p38MAPK and PPAR/. A, B: ECs were serum depleted for 1 h, 
pretreated (1 h) with vehicle, 1 M Akt1/2i, or both GSK0660 and SB202190 (each 1 M) then incubated with remnant control (Control) 
or DHASCO® A-CRLPs (280 M TG) in the continued absence/presence of inhibitor(s) for 4 h. Cells were immunostained for Nrf2 (red) 
and nuclei labeled with DAPI (blue). No staining was evident in secondary antibody-only controls (not shown). Representative images are 
in (A) and combined mean nuclear Nrf2 fluorescence intensities from three separate images per condition are shown in (B) (mean ± 
SEM). C–E: Serum-starved HAECs were preincubated with vehicle or both 1 M GSK0660 and 1 M SB202190 (GSK+SB) for 1 h then 
incubated with A-CRLPs in the presence of vehicle or inhibitors for 4 h. C: Representative HO-1 and -actin blots: vehicle (v), GSK+SB (++). 
D, E: HO-1 mRNA expression normalized to GAPDH. Data are fold change relative to remnant control (RC) (mean ± SEM, n = 3). Two-
way ANOVA with Bonferroni’s multiple comparisons test: vehicle versus GSK+SB: $P < 0.05, $$P < 0.01, $$$$P < 0.0001. RC versus A-CRLP: 
*P < 0.05, **P < 0.01, ****P < 0.0001.
 by guest, on August 17, 2016
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2016/05/16/jlr.M067108.DC1
Supplemental Material can be found at:
1214 Journal of Lipid Research Volume 57, 2016
expression of cytoprotective genes, A-CRLPs had no detri-
mental effects on HAEC viability, so the ROS generated in 
response to these particles likely act as physiological sig-
naling molecules rather than reflecting deleterious “oxi-
dative stress” or lipid oxidation within ECs, cells which rely 
primarily on glycolysis and not on FA oxidation for energy 
(51). Probucol itself can also induce HO-1 independently 
of its antioxidant properties (52), which may explain the 
residual HO-1 induction by probucol-fish and -DHASCO® 
A-CRLPs despite no detectable increase in ROS.
Together, our data demonstrate that both oxidation 
state and TG composition are important determinants of 
the EC response to model artificial CMRs. However, the 
lipid species and/or oxidation products mediating the 
differential effects of the A-CRLP types studied on EC 
gene expression have yet to be identified and are currently 
being investigated using lipidomics approaches. There are 
numerous potential candidates because, in addition to any 
direct effects of A-CRLP constituents (oxidized or other-
wise) and of products of spontaneous oxidation in ECs, 
the activities of lipid-metabolizing enzymes, such as cyclo-
oxygenases, lipoxygenases, and epoxygenases, operative 
in ECs, generate a plethora of oxidized FA metabolites that 
may contribute to the altered cell signaling and downstream 
gene expression described here. The specific oxidized lipid 
species contributing to the adaptive antioxidant/protective 
response triggered in ECs by n-3 PUFA-containing A-CRLPs 
are of particular interest. In this respect, it has been 
reported that oxidized DHA, itself, shows a greater ability 
to activate Nrf2 and induce NADPH quinone oxidoreduc-
tase-1 expression than parent DHA (53), suggesting that 
the more efficacious effects of n-3 PUFA-enriched A-CRLPs 
reported here could involve the actions of oxidized n-3 
PUFAs. The residual HO-1 expression evident in ECs 
exposed to probucol-containing A-CRLPs also lends 
support to the notion that either the PUFAs themselves 
are partially responsible and/or that lipid oxidation occurs 
at the cell surface/within ECs following delivery of the PUFAs 
in TG form via the lipoproteins.
A combination of pharmacological and siRNA ap-
proaches strongly implicated NOX4, highly expressed by 
ECs (40, 54), as a driver of HO-1 expression by A-CRLPs. 
Interestingly, NOX4 mRNA expression was reduced by 
DHASCO® A-CRLPs and increased by palm CRLPs, in 
keeping with previous studies demonstrating that non-
esterified DHA decreases, whereas palmitate increases, 
NOX4 (55, 56) and suggesting that redox regulatory 
feedback mechanisms involving altered NOX4 expression 
may be operating in a TG-dependent manner in ECs. 
MitoTEMPO, a mitochondrial superoxide scavenger, also 
reduced A-CRLP-stimulated HO-1 expression, most sig-
nificantly for n-3 PUFA-rich particles, with no effect on the 
response to palm A-CRLPs. Thus, our data suggest that 
NOX4 activity and mitochondrial ROS regulate HO-1 
induction by A-CRLPs, with SFA-rich palm A-CRLPs induc-
ing HO-1 primarily via NOX4 and n-3 PUFA-rich A-CRLPs 
using both mechanisms to upregulate endothelial HO-1. 
While it is known that inappropriate expression of NOX4 
can lead to redox imbalance and pathology (57), the 
with protective, anti-apoptotic, and anti-inflammatory 
actions (29, 32) and HO-1 deficiency is associated with 
accelerated endothelial dysfunction and atherosclerosis 
(27–32). Thus, the predominant and strong induction of 
HO-1 by n-3 PUFA-containing A-CRLPs, compared with 
those enriched in n-6 PUFAs or SFAs, suggests that a par-
ticularly robust antioxidant defense program may be trig-
gered by EC exposure to TRL-associated n-3 PUFAs, changes 
that were mirrored by reduced expression of genes with 
known pro-inflammatory functions (VCAM-1 and TXNIP).
Silencing of Nrf2 confirmed its importance in A-CRLP-
induced HO-1 induction. Also, Nrf2 protein was induced 
by n-3 PUFA-containing A-CRLPs, but we detected no 
change in Nrf2 mRNA, as reported for oxidant-induced 
Nrf2 (47), likely due to tight regulation of Nrf2 at the 
translational level via internal ribosome entry site-mediated 
translation and/or other mechanisms (48, 49). The rela-
tionship between enhanced HO-1 induction and the al-
tered inflammatory potential identified here now requires 
exploration, as does efficacy in vivo, but it can be specu-
lated that these endothelial-directed effects of n-3 PUFA-
containing A-CRLPs may have mechanistic relevance for 
the actions of physiological TRLs in vivo and could help to 
explain the reported beneficial actions of dietary n-3 PU-
FAs on vascular homeostasis (3, 16). Indeed, in other func-
tional studies directly comparing the EC-directed actions 
of A-CRLPs with those of physiological TRLs, we have 
established that CMR-rich TRL fractions isolated from hu-
mans following ingestion of high-fat meals supplemented 
with n-3 PUFAs (15) recapitulate the protective effects of 
n-3 PUFA A-CRLPs by upregulating antioxidant defense 
and have shown that HO-1 induction is linked to suppressed 
inflammation, notably reduced cytokine-stimulated adhe-
sion molecule expression and monocyte adhesion to ECs, 
and improved EC survival (R. Purcell et al., unpublished 
observations). Nonesterified DHA has been reported to 
inhibit the modest increases in EC VCAM-1 expression 
elicited by “atherogenic” mixtures of TRLs isolated from 
hyperlipidemic individuals (50), but our study is the first 
demonstrating that a tractable artificial model of CMRs 
triggers protective responses in adult ECs according to 
FA content.
It is possible that the quantitatively dissimilar effects of 
the different A-CRLPs on HO-1 induction reflect the over-
all level of unsaturation of their constituent FAs, although 
this cannot be the full explanation, as n-6 PUFA corn 
A-CRLPs  lead  to equivalent ROS production  to fish and 
DHASCO® A-CRLPs (as detected using DHR), yet this did 
not correlate directly with their relative effects on HO-1 
expression or their oxidative state indicated by TBARS 
content (n-3 PUFA A-CRLPs > n-6 PUFA A-CRLPs). Oxida-
tion of the relatively n-6 PUFA-rich corn A-CRLPs may 
occur more slowly than the n-3 PUFA-containing particles, 
potentially explaining the difference in their TBARS con-
tents. In addition, all A-CRLPs, including the SFA-rich par-
ticles, affected TXR and NADPH quinone oxidoreductase-1 
expression to an equivalent extent after 16 h, despite the 
lower ability of SFA CRLPs to induce ROS compared with 
the other CRLPs. In keeping with their action to increase 
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expression, consistent with a growing body of evidence 
linking p38MAPK activation to cell survival and oxidative 
stress  resistance (24, 43, 60–62). The  significance of  the 
A-CRLP-induced  increases  in  Akt  and  ERK1/2  activities 
remains to be determined, but these could be important 
for transcriptional regulation of other gene targets iden-
tified in A-CRLP-treated HAECs and, thus, for the func-
tional outcomes of A-CRLP exposure, which are currently 
under investigation.
PPAR/ is a lipid ligand-inducible transcription factor 
with established roles in the regulation of lipid metabo-
lism and endothelial function (44, 63). Although there is 
poor understanding of its specific involvement in nutrient 
sensing by ECs and subsequent alterations in gene expres-
sion, there is evidence that a wide range of FAs can directly 
activate PPAR/ (64, 65). Here, PPAR/-deficient HAECs 
showed a blunted response to A-CRLPs, demonstrating that 
NOX4/Nrf2-dependency of protective HO-1 induction by 
A-CRLPs reported here is wholly consistent with recent 
evidence  in murine models  that  NOX4,  when  specifi-
cally coupled to Nrf2 activation, protects the heart dur-
ing chronic pressure overload (58) and that endothelial 
NOX4 provides endogenous protection from atheroscle-
rosis development (59).
We showed that HAECs exposed to A-CRLPs exhibited 
enhanced phosphorylation of Akt, ERK1/2, and p38MAPK, 
implicating these kinases in the control of ECs by dietary 
FAs. Given the known pro-survival actions of the Akt and 
MEK-ERK signaling pathways, we hypothesized that these 
might be key mediators of the antioxidant defense re-
sponses triggered by A-CRLPs. However, although Akt1 
appears to regulate basal HO-1 expression, we found 
that p38MAPK is the dominant pathway coupled to down-
stream regulation of A-CRLP-driven Nrf2-dependent HO-1 
Fig. 7.  Summary of results: proposed mechanisms mediating the effects of A-CRLPs on HAECs. Artificial 
model TRLs resembling CMRs (A-CRLPs) upregulate several antioxidant and cytoprotective genes in HAECs 
with the most efficacious effects evident with A-CRLPs containing TG extracted from n-3 PUFA-containing 
oils. A-CRLPs regulate HO-1 induction in HAECs through a NOX4-driven pathway involving downstream 
activation of p38MAPK and parallel activation of the nuclear receptor superfamily member, PPAR/. This 
results in increased Nrf2 expression and nuclear translocation, culminating in transcriptional upregulation 
of HO-1 and of other protective/antioxidant genes  (e.g.,  SRX and TXR). We also  showed  that A-CRLP-
driven HO-1 induction in HAECs is accompanied by reduced expression of the pro-inflammatory adhesion 
molecule, VCAM-1. The lipid species mediating activation of this redox-dependent pathway are yet to be 
clarified, but it is reasonable to speculate that oxidized FA/lipids acting directly on ECs following metabo-
lism of TG-rich A-CRLPs at the cell surface and/or enzymatic products of FA/lipid oxidation generated 
intracellularly following particle uptake play key roles. Because HO-1 has known anti-inflammatory and 
cytoprotective functions, TRLs carrying n-3 PUFAs may act to suppress inflammatory changes in the endothe-
lium and maintain cell survival in the postprandial phase, thus moderating the postprandial inflammation 
associated with fat consumption.
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PPAR/ is a pivotal mediator of A-CRLP-stimulated HO-1 
induction in adult ECs. The precise mechanisms leading 
to PPAR/ activation require clarification but, as dis-
cussed above, FAs and/or their oxidation products deliv-
ered  to ECs by A-CRLPs or  subsequently generated by 
enzymatic processes within ECs are likely to directly acti-
vate PPAR/. Given that PUFAs are more potent ligands 
of PPAR/  than  SFAs  (44),  our finding  that  PPAR/ 
regulates HO-1 induction by A-CRLPs irrespective of their 
FA composition may reflect the fact that TGs extracted 
from the four natural oils are complex mixtures of FAs 
present within the model artificial CMRs, alongside cho-
lesterol, esterified cholesterol, and phospholipids. Our 
observation that PPAR/ plays a role in HO-1 induction 
by A-CRLPs is consistent with reports that endothelial-
specific  PPAR/ deletion in mice is associated with 
reduced expression of protective genes and heightened 
inflammation (66), and that direct pharmacological acti-
vation of PPAR/ increases HO-1 expression in fetal 
ECs and murine aorta ex vivo (46, 67).
The modest stimulation of HO-1 induction by SFA-rich 
palm CRLPs, together with their lack of effect on cell via-
bility, suggest that these particles are not overtly deleteri-
ous to ECs, contrasting with reports  that nonesterified 
palmitate alone drives lipotoxicity and EC dysfunction in 
vitro (68). However, it is noteworthy that HO-1 induction 
in response to SFA A-CRLPs was accompanied both by 
increased expression of E-selectin (detected in the array; 
validation not shown) and by enhanced NOX4 expression 
after more prolonged incubation. Thus, while some com-
mon cytoprotective pathways appeared to be triggered by 
all the A-CRLP types studied, albeit to different extents, 
other divergent effects occurring in parallel will likely dic-
tate the overall outcome of endothelial exposure to parti-
cles with distinct TG compositions.
Collectively, our data are consistent with a mechanism 
in which A-CRLP treatment results in activation of NOX4 
leading to redox-dependent activation of p38MAPK and par-
allel activation of the lipid sensor, PPAR/ (see Fig. 7). 
This results in increased Nrf2 expression and activity and 
transcriptional regulation of HO-1 and other protective 
genes. Activation of a NOX4-Nrf2-HO-1 axis triggered by 
dietary-derived TRLs in vivo may, therefore, be fundamen-
tally important for adaptive protection of the vessel wall in 
the postprandial phase and for mitigating the postprandial 
inflammation thought to encourage development of endo-
thelial dysfunction and its detrimental consequences (3).
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